AstraZeneca PLC (AZN)vsMettler-Toledo International Inc (MTD)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
MTD
Mettler-Toledo International Inc
$1,240.15
-1.77%
HEALTHCARE · Cap: $25.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1359% more annual revenue ($58.74B vs $4.03B). MTD leads profitability with a 21.6% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.54. MTD earns a higher WallStSmart Score of 66/100 (B-).
AZN
Buy64
out of 100
Grade: C+
MTD
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-63.3%
Fair Value
$853.06
Current Price
$1240.15
$387.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 30.7%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 22 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : MTD
The strongest argument for MTD centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 21.6% and operating margin at 30.7%.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : MTD
The primary concerns for MTD are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a value stock while MTD is a mature play — different risk/reward profiles.
MTD carries more volatility with a beta of 1.44 — expect wider price swings.
MTD is growing revenue faster at 8.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
MTD scores higher overall (66/100 vs 64/100), backed by strong 21.6% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Mettler-Toledo International Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mettler Toledo (NYSE: MTD) is a multinational manufacturer of scales and analytical instruments. It is the largest provider of weighing instruments for use in laboratory, industrial, and food retailing applications. The company also provides various analytical instruments, process analytics instruments, and end-of-line inspection systems.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?